Treatment

The regulatory role of nicotinic receptors in cognitive functioning

The importance of using systems biology based approaches in AD research

How effective are cholinergic agents beyond MCI?

Highlights from CTAD 2022

Prioritizing the mechanistic understanding of AD to improve treatments

Photobiomodulation: why target the brain and the gut?

APOE-targeted epigenome therapy for Alzheimer’s disease

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD

Lecanemab and what this means for the future treatment of Alzheimer’s disease

Ensuring the safety of epigenome therapies in the treatment of Alzheimer’s disease

Future direction for anti-amyloid immunotherapies

What’s next for clinical trials in Alzheimer’s disease?

Precision medicine in Alzheimer’s treatment: genetics and co-pathologies

Lipidomics as a tool for dementia research

Nilotinib: a potential repurposed treatment for Alzheimer’s disease?